SE0103795D0 - Compounds and method for the treatment of överactive bladder - Google Patents

Compounds and method for the treatment of överactive bladder

Info

Publication number
SE0103795D0
SE0103795D0 SE0103795A SE0103795A SE0103795D0 SE 0103795 D0 SE0103795 D0 SE 0103795D0 SE 0103795 A SE0103795 A SE 0103795A SE 0103795 A SE0103795 A SE 0103795A SE 0103795 D0 SE0103795 D0 SE 0103795D0
Authority
SE
Sweden
Prior art keywords
compounds
sup
treatment
overactive bladder
disclosed
Prior art date
Application number
SE0103795A
Other languages
English (en)
Swedish (sv)
Inventor
Cathy Dantzman
Keith Herzog
Russell Bialecki
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0103795A priority Critical patent/SE0103795D0/xx
Publication of SE0103795D0 publication Critical patent/SE0103795D0/xx
Priority to ES02783904T priority patent/ES2282491T3/es
Priority to DE60218203T priority patent/DE60218203T2/de
Priority to CNA028265696A priority patent/CN1610676A/zh
Priority to AT02783904T priority patent/ATE353886T1/de
Priority to MXPA04004075A priority patent/MXPA04004075A/es
Priority to US10/494,195 priority patent/US7368461B2/en
Priority to IL16160002A priority patent/IL161600A0/xx
Priority to PCT/SE2002/001991 priority patent/WO2003037889A1/en
Priority to CA002465429A priority patent/CA2465429A1/en
Priority to BR0213832-8A priority patent/BR0213832A/pt
Priority to KR10-2004-7006520A priority patent/KR20040053239A/ko
Priority to JP2003540170A priority patent/JP2005511571A/ja
Priority to EP02783904A priority patent/EP1444220B1/en
Priority to ZA200403206A priority patent/ZA200403206B/en
Priority to NO20042138A priority patent/NO20042138L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE0103795A 2001-11-02 2001-11-02 Compounds and method for the treatment of överactive bladder SE0103795D0 (sv)

Priority Applications (16)

Application Number Priority Date Filing Date Title
SE0103795A SE0103795D0 (sv) 2001-11-02 2001-11-02 Compounds and method for the treatment of överactive bladder
EP02783904A EP1444220B1 (en) 2001-11-02 2002-11-01 Compounds and method for the treatment of overactive bladder
US10/494,195 US7368461B2 (en) 2001-11-02 2002-11-01 Compounds and method for the treatment of overactive bladder
PCT/SE2002/001991 WO2003037889A1 (en) 2001-11-02 2002-11-01 Compounds and method for the treatment of overactive bladder
CNA028265696A CN1610676A (zh) 2001-11-02 2002-11-01 用于治疗膀胱活动过度的化合物和方法
AT02783904T ATE353886T1 (de) 2001-11-02 2002-11-01 Verbindungen und verfahren zur behandlung einer hyperaktiven blase
MXPA04004075A MXPA04004075A (es) 2001-11-02 2002-11-01 Compuesto y metodo para tratamiento de vejiga hiperactiva.
ES02783904T ES2282491T3 (es) 2001-11-02 2002-11-01 Compuestos y metodo para el tratamiento de la vejiga hiperactiva.
IL16160002A IL161600A0 (en) 2001-11-02 2002-11-01 Compounds and method for the treatment of over-active bladder
DE60218203T DE60218203T2 (de) 2001-11-02 2002-11-01 Verbindungen und verfahren zur behandlung einer hyperaktiven blase
CA002465429A CA2465429A1 (en) 2001-11-02 2002-11-01 Compounds and method for the treatment of overactive bladder
BR0213832-8A BR0213832A (pt) 2001-11-02 2002-11-01 Composto, método para tratamento ou prevenção de bexiga superativa ou incontinência urinária em um indivìduo, composição farmacêutica, e, uso de (s)-n-[2-(3,4-diclorofenil)-4-[4-(2-oxo-piperidin-1-il)piperi dino]butil]-n-metil-2-fluorobenzamida ou um sal farmaceuticamente aceitável da mesma
KR10-2004-7006520A KR20040053239A (ko) 2001-11-02 2002-11-01 과활동성 방광의 치료를 위한 화합물 및 치료 방법
JP2003540170A JP2005511571A (ja) 2001-11-02 2002-11-01 過活動膀胱の治療のための化合物および方法
ZA200403206A ZA200403206B (en) 2001-11-02 2004-04-28 Compounds and method for the treatment of overactive bladder.
NO20042138A NO20042138L (no) 2001-11-02 2004-05-25 Forbindelser og fremgangsmate for behandling av hyperaktiv blaere

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103795A SE0103795D0 (sv) 2001-11-02 2001-11-02 Compounds and method for the treatment of överactive bladder

Publications (1)

Publication Number Publication Date
SE0103795D0 true SE0103795D0 (sv) 2001-11-02

Family

ID=20285984

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0103795A SE0103795D0 (sv) 2001-11-02 2001-11-02 Compounds and method for the treatment of överactive bladder

Country Status (16)

Country Link
US (1) US7368461B2 (ja)
EP (1) EP1444220B1 (ja)
JP (1) JP2005511571A (ja)
KR (1) KR20040053239A (ja)
CN (1) CN1610676A (ja)
AT (1) ATE353886T1 (ja)
BR (1) BR0213832A (ja)
CA (1) CA2465429A1 (ja)
DE (1) DE60218203T2 (ja)
ES (1) ES2282491T3 (ja)
IL (1) IL161600A0 (ja)
MX (1) MXPA04004075A (ja)
NO (1) NO20042138L (ja)
SE (1) SE0103795D0 (ja)
WO (1) WO2003037889A1 (ja)
ZA (1) ZA200403206B (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200508221A (en) 2003-06-13 2005-03-01 Astrazeneca Ab New azetidine compounds
DE102004001873A1 (de) * 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
WO2006121389A1 (en) * 2005-05-10 2006-11-16 Astrazeneca Ab Use of a neurokinin-2 receptor antagonist for treating or preventing detrusor overactivity
AR057828A1 (es) 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
US8106208B2 (en) 2006-05-18 2012-01-31 Albireo Ab Benzamide compounds that act as NK receptor antagonists
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
CN112915266B (zh) * 2021-02-05 2021-11-09 武汉磁济科技有限公司 一种人工膀胱铁磁复合体及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321557D0 (en) * 1992-11-03 1993-12-08 Zeneca Ltd Carboxamide derivatives
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
GB9322643D0 (en) * 1993-11-03 1993-12-22 Zeneca Ltd Lactam derivatives
GB9421709D0 (en) * 1994-10-27 1994-12-14 Zeneca Ltd Therapeutic compounds
US6008223A (en) * 1994-10-27 1999-12-28 Zeneca Limited Therapeutic compounds
GB9505084D0 (en) * 1995-03-14 1995-05-03 Pfizer Ltd Benzamide derivative
GB9922519D0 (en) * 1998-10-07 1999-11-24 Zeneca Ltd Compounds
GB9924141D0 (en) * 1998-10-30 1999-12-15 Zeneca Ltd Treatment of gastric asthma
WO2000034234A1 (fr) * 1998-12-04 2000-06-15 Rimma Iliinichna Ashkinazi Aryl- et heteroarylamides d'acides carboalcoxysulfaniliques
GB9826941D0 (en) 1998-12-09 1999-02-03 Zeneca Pharmaceuticals Compounds
GB0015246D0 (en) * 2000-06-22 2000-08-16 Astrazeneca Ab Method for the treatment of urinary incontinence

Also Published As

Publication number Publication date
WO2003037889A8 (en) 2004-05-06
US7368461B2 (en) 2008-05-06
CA2465429A1 (en) 2003-05-08
DE60218203T2 (de) 2008-01-03
ZA200403206B (en) 2005-02-22
DE60218203D1 (de) 2007-03-29
IL161600A0 (en) 2004-09-27
US20050203113A1 (en) 2005-09-15
BR0213832A (pt) 2004-08-31
CN1610676A (zh) 2005-04-27
WO2003037889A1 (en) 2003-05-08
KR20040053239A (ko) 2004-06-23
EP1444220B1 (en) 2007-02-14
EP1444220A1 (en) 2004-08-11
NO20042138L (no) 2004-05-25
MXPA04004075A (es) 2004-07-23
ES2282491T3 (es) 2007-10-16
ATE353886T1 (de) 2007-03-15
JP2005511571A (ja) 2005-04-28

Similar Documents

Publication Publication Date Title
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2003037271A3 (en) Compounds, pharmaceutical compositions and methods of use therefor
DE60039508D1 (de) Methoden zur behandlung der essstörungen
RS50814B (sr) Tartaratne soli 5,8,14-triazatetraciklo(10.3.1.02,11.04,9)- heksadeka-2(11),3,5,7,9-pentaena
DZ3186A1 (fr) Ptéridinones utilisées comme inhibiteurs de kinase.
NO2013017I2 (no) (a)dekstrometorfan eller et farmasøytisk akseptabelt salt derav, for eksempel dekstrometorfanhydrobromid og (b) quinidin eller etfarmasøytisk akseptabelt salt derav, for eksempel quinidinsulfat
CY1108885T1 (el) Συνδυασμοι περιλαμβανοντες αντιμουσκαρινους παραγοντες και κορτικοστεροειδη
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
DE60324544D1 (de) Muskarin antagonisten
EA200400734A1 (ru) Способ и композиция для потенциирования действия опиатного анальгетика
NO20012194D0 (no) CRF-reseptorantagonister og tilhörende fremgangsmåter
TR200102178T2 (tr) CRF reseptör antagonistleri ve bunlarla ilgili yöntemler.
SE0003476D0 (sv) Compounds
SE0103795D0 (sv) Compounds and method for the treatment of överactive bladder
MXPA02000330A (es) Pirrolidinas y piperidinas neurotroficas y composiciones y metodos relacionados.
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
BRPI0406734A (pt) Composição termiticida, e, método para controlar térmitas
EP1642576A3 (en) Methods, kits and compositions for using pyrrole derivatives to combat anxiety
GB0015246D0 (en) Method for the treatment of urinary incontinence
MXPA04004071A (es) Metodo para tratamiento de vejiga hiperactiva.
DE60236927D1 (de) Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba
DK1156795T3 (da) Anvendelse af ravsyre eller salte deraf, og fremgangsmåde til behandling af insulinresistens
ATE260918T1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
DE602004030536D1 (de) Pyrrolidinohydrochinazoline
WO2001068066A3 (en) A composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer